Interruption of the CCK-BR signaling pathway with proglumide not only inhibits the proliferation of pancreatic cancer epithelial cells and tumors [39] but also decreases the function of activated PSCs, thus providing a two-for-one hit therapeutic for pancreatic cancer. This evidence concerns the gene CCK and familial pancreatic carcinoma.